

Antonio Grizzuti

ask+request-8418-37140913@asktheeu.org

Stockholm, 14 September 2020

Our ref.: DPR-2020-OUT-3139-KEElKh

Dear Mr. Grizzuti,

Re: Your application for access to documents – Ref 20-3292

We refer to your e-mail dated 3 August 2020 in which you make a request for access to documents, registered on the same day under the above mentioned reference number.

I. Scope of your request

You request access to documents that contain the following information:

- the full and detailed correspondence between (from and to) ECDC and Italian Department of Health (Ministero della Salute), and any of its officer (including minister Mr Roberto Speranza) related to "Wuhan

unknown pneumonia", Sars-CoV-2 and Covid-19, starting from January 1st, 2020 since today;

- the full and detailed correspondence between (fron and to) ECDC and any Italian government, included

Office of the Prime Minister, Protezione Civile, and each Department, related to "Wuhan unknown

pneumonia", Sars-CoV-2 and Covid-19, starting from January 1st, 2020 since today

Let us now explain which actions ECDC took to satisfy your request.

We ran a search through the several functional mailboxes that ECDC has dedicated to manage all the

correspondence related to COVID-19, in order to find the correspondence between ECDC and the institutions mentioned in your request, by checking correspondence with email addresses ending with ".it" which belong

to any those institutions and containing any of the parameters mentioned in your request ("Wuhan unknown

pneumonia", Sars-CoV-2 and Covid-19).

II. Documents that ECDC has identified

We have identified the following documents falling under the scope of your request. Please note that the

vast majority of emails are communications between ECDC and numerous recipients, especially the "national focal points" and "operational contact points" of the different networks led by ECDC and/or various national

competent bodies, among which are include some of the Italian institutions mentioned in your application.

1/7

Emails found in the mailboxes dedicated to COVID-19 and attached documents, if applicable:

- 1. ECDC survey on socially and medically vulnerable populations in the EU_EEA and the UK during the Covid-19 pandemic
- 1.1. Attachment: Data Privacy Statement_ECDC Survey
- 2. For validation and information_ ECDC Technical report "COVID-19 clusters and outbreaks in occupational settings in the EU_EEA and the UK"
- 2.1. Attachment: COVID-19 in Occupational settings_DRAFT_27 July 2020
- 3. Guidance on medically and socially vulnerable populations
- 4. Constitution of an Internal Response Team for the production of the Rapid Risk Assessment _resurgence of cases of COVID-19 in the EU_EEA, the UK and EU candidate and potential candidate countries
- 5. Constitution of an Internal Response Team for the production of a Threat Assessment Brief_ Pneumonia cases of unknown aetiology in Wuhan, China
- 6. ECDC COVID-19 update 15 02 2020
- 6.1. Attachment: COVID-19_20200215
- 7. ECDC_ COVID-19 update 16_02_2020
- 7.1. Attachment: COVID-19_20200216
- 8. ECDC_ COVID-19 update 17_02_2020
- 8.1. Attachment: COVID-19_20200217
- 9. ECDC COVID-19 update
- 9.1. Attachment: COVID-19_20200213
- 10. ECDC COVID-19 update 18.02.2020
- 10.1. Attachment: COVID-19_20200218(RT)
- 11. ECDC COVID-19 update 14 02 2020
- 11.1. Attachment: COVID-19_20200214
- 12. ECDC_ COVID-19 update as of 19_02_2020
- 12.1. Attachment: COVID-19_20200219(EC)
- 13. FYI prior to publication Rapid Risk Assessment "Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children
- 13.1. Attachment: ECDC_RRA_Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children

- 14. FYI prior to publication Threat Assessment Brief_ Pneumonia cases possibly associated to a novel coronavirus in Wuhan, China
- 14.1. Attachment: ECDC Threat Assessment Brief Pneumonia cases possibly associated to a novel coronavirus in Wuhan China
- 15. FYI prior to publication- ECDC rapid risk assessment _Resurgence of reported cases of COVID-19 in several of the EU EEA, the UK and EU candidate and potential candidate countries
- 15.1. Attachment: RRA_ECDC_COVID-19 resurgence in EU-EEA the UK and EU candidate and potential candidate countries_20200701
- 16. FW_ FYI prior to publication- ECDC assessment on risk of COVID-19 for the EU_EEA and UK population, 11th update
- 17. To OCPs for Influenza and COVID-19 for action outbreaks related to occupational settings
- 17.1. Attachment: OccupationalOutbreakData
- 18. Reminder_ To OCPs for Influenza and COVID-19 for action_ outbreaks related to occupational settings 18.1. Attachment: OccupationalOutbreakData
- 19. To the OCPs for Influenza and COVID-19 for feedback_ investigations on role of children and educational settings
- 20. ECDC COVID-19 update as of 31 July 2020
- 20.1. Attachment: COVID-19_20200731(EC)
- 21. Go.Data use for COVID-19 contact tracing in the EU_EEA and the United Kingdom
- 21.1. Attachment: Go.Data 2 pager 2020-01-29
- 21.2. Attachment: Go.Data Introduction 2020-01-29
- 22. RE Go.Data use for COVID-19 contact tracing in the EU_EEA and the United Kingdom
- 22.1. Attachment: Go.Data 2 pager 2020-01-29
- 22.2. Attachment: Go.Data Introduction 2020-01-29
- 23. FW EU NITAG COLLABORATION INVITATION TO DIALOGUE WITH EMA ON PUBLIC HEALTH ASPECTS OF SARS-CoV-2 VACCINES MONDAY 15 JUNE 1300 1500 (closed meeting)
- 23.1. Attachment: Annex COVID-19_NITAGs_EMA
- 23.2. Attachment: DRAFT Vaccine prioritisation opinion (EC req 87)

The attachment called "2020-06-08 – Letter to Dr Andrea Ammon, ECDC Director – Meeting request ECDC and NITAGs" is a communication between the European Medicines Agency (EMA) and ECDC, which does not fall under the scope of the request.

24. R_ Pneumonia cases possibly associated to a novel coronavirus in Wuhan, China

- 25. For validation and information_ ECDC TR _COVID-19 in children and the role of school settings in COVID-
- 19 transmission_ and _Testing for COVID-19 in school settings.
- 25.1. Attachment: ECDC_Schools and COVID-19 transmission_draft
- 25.2. Attachment: ECDC COVID-19 school testing guidelines_draft
- 26. IMPORTANT change for your attention! For validation and information_ ECDC Technical report _Testing for COVID-19 in school settings
- 26.1. Attachment: EC request_school testing guidelines_draft
- 27. FW_ COVID-19 Laboratory Networks Meeting
- 28. FW_ Joint ECDC and WHO_Europe WebEx on COVID-19 sero-epidemiological studies
- 28.1. Attachment: Notes from meeting 27.04.2020
- 28.2. Attachment: Seroepidemiology studies in EU 20200427
- 29. FW_ Joint ECDC_WHO Europe network TC for updates on COVID-19
- 30. RE_ Reminder_ COVID-19 diagnostics minimum performance criteria survey, by Monday 1 June
- 31. FW Joint ECDC and WHOEurope Global Webinar on strategies for testing asymptomatic for COVID19
- 32. FW_ WebEx_ EU_EEA collaboration on COVID-19 sero-epidemiological studies
- 32.1. Attachment: Terms of reference
- 33. ECDC CDTR 29.05.2019
- 33.1. Attachment: Communicable-disease-threats-report-30-may-2020-restricted
- 34. ECDC CDTR 01.01.2020 week 2
- 34.1. Attachment: ECDC_CDTR_20200110_RESTRICTED
- 35. ECDC CDTR 10.07.2020
- 35.1. Attachment: Communicable-disease-threats-report-11-july-2020- RESTRICTED
- 36. ECDC CDTR 12.06.2020
- 36.1. Attachment: ECDC CDTR w24
- 37. ECDC CDTR 17 04 2019
- 37.1. Attachment: Communicable-disease-threats-report-18-apr-2020-RESTRICTED
- 38. ECDC CDTR 17.07.2020
- 38.1. Attachment: CDTR_WEB_ALL_2020_7_12

Phone: +46 (0)8 58 60 10 00 - Fax: +46 (0)8 58 60 10 01

- 39. ECDC CDTR 18.06.2019 week 25
- 39.1. Attachment: CDTR_WEB_ALL_2020_6_14
- 40. ECDC CDTR 20.05.2020
- 40.1. Attachment: CDTR_EWRS_2020_5_17
- 41. ECDC CDTR 27.03.2020
- 41.1. Attachment: ECDC CDTR 27.03.2020
- 42. ECDC CDTR 3.7.2020
- 42.1. Attachment: CDTR_EWRS_2020_6_28
- 43. ECDC CDTR 7 February 2020
- 43.1. Attachment: ECDC CDTR_07022020
- 44. ECDC CDTR 13 March 2019
- 44.1. Attachment: ECDC_CDTR_2020-03-13
- 45. ECDC CDTR 17 Jan 2020, week 3
- 45.1. Attachment: CDTR_ECDC_17Jan2020
- 46. ECDC CDTR 21.02.2019
- 46.1. Attachment: CDTR-22-Feb-2020-RESTRICTED
- 47. ECDC CDTR 24 January 2019
- 47.1. Attachment: ECDC_CDTR_24January2020
- 48. ECDC CDTR 26.06.2020 week 26 Redacted
- 48.1. Attachment: ECDC_CDTR_2020w26_restricted
- 49. ECDC CDTR 31.01.2020
- 49.1. Attachment: ECDC CDTR 31.01.2020
- 50. ECDC CDTR 2020 week 12
- 50.1. Attachment: Communicable-disease-threats-report-21-mar-2020-RESTRICTED
- 51. ECDC CDTR 2020 week 14
- 51.1. Attachment: Communicable-disease-threats-report-4-apr-2020-RESTRICTED
- 52. ECDC CDTR 2020 week 19
- 52.1. Attachment: Communicable-disease-threats-report-9-may-2020-RESTRICTED
- 53. ECDC CDTR, Week 23, 05.06.2020

53.1. Attachment: ECDC CDTR 20200605

54. ECDC CDTR Week 31, 2020

54.1. Attachment: CDTR_EWRS_2020_7_31

55. ECDC CDTR Week 32 07.08.2020

The attached document is a draft. The final document was published on ECDC website and can be found on the link below. The information regarding COVID-19 has not changed.

https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-2-8-august-2020-week-32

56. R_ R_ Pneumonia cases of unknown aetiology – Wuhan, China – 2019

III. Redaction of documents

The documents to which you have requested access contain personal data, in particular the name and/or contact details of authors of the document, and/or of staff members of ECDC and/or third parties (including Italian authorities or other ECDC stakeholders, or WHO staff) that are mentioned in the document or included in a specific correspondence.

Pursuant to Article 4(1) (b) of Regulation (EC) No 1049/2001, access to a document has to be refused if its disclosure would undermine the protection of privacy and the integrity of the individual, in particular in accordance with Union legislation regarding the protection of personal data. The applicable legislation in this field is Regulation (EU) No 2018/1725.

When access is requested to documents containing personal data, Regulation (EU) No 2018/1725 becomes fully applicable. According to Article 9.1(b) of this Regulation, personal data shall only be transferred to recipients if they establish the necessity of having the data transferred to them and if there is no reason to assume that the legitimate rights of the persons concerned might be prejudiced.

We consider that, with the information available, the necessity of disclosing the aforementioned personal data to you has not been established and/or that it cannot be assumed that such disclosure would not prejudice the legitimate rights of the persons concerned. Therefore, we are disclosing the documents requested expunged from this personal data. In particular, we have redacted all the personal data of individuals included in the documents (names, contact details, emails, etc.), except where the personal data is already publicly available and known (e.g. the name of the ECDC Director).

As for document number 27, which includes two attachments, ECDC has decided that these attachments should not be released, as they include commercially sensitive information on commercial trial evaluation results on COVID-19. The denial of access to these documents is covered by article 4.2 of Regulation 1049/2001, which states that "the institutions shall refuse access to a document where disclosure would undermine the protection of commercial interests of a natural or legal person, including intellectual property",

6/7

as occurs in the present case. Furthermore, we consider that the partial disclosure of these attached documents is not applicable in this case.

IV. Means of redress

In accordance with Article 7(2) of Regulation (EC) No 1049/2001, you are entitled to make a confirmatory application requesting the ECDC to review this position.

Such a confirmatory application should be addressed within 15 working days upon receipt of this letter to the following address:

ECDC

Legal Services

Gustav III:s Boulevard 40

16973 Solna

Sweden

or by email to: confirmatory.requests@ecdc.europa.eu.

Yours faithfully,



Head of Unit Disease Programmes

and Cholale

Encl.: Documents 1, 1.1, 2, 2.1, 3, 4, 5, 6, 6.1, 7, 7.1, 8, 8.1, 9, 9.1, 10, 10.1, 11, 11.1, 12, 12.1, 13, 13.1, 14, 14.1, 15, 15.1, 16, 17, 17.1, 18, 18.1, 19, 20, 20.1, 21, 21.1, 21.2, 22, 22.1, 22.2, 23, 23.1, 23.2, 24, 25, 25.1, 25.2, 26, 26.1, 27, 28, 28.1, 28.2, 29, 30, 31, 32, 32.1, 33, 33.1, 34, 34.1, 35, 35.1, 36, 36.1, 37, 37.1, 38, 38.1, 39, 39.1, 40, 40.1, 41, 41.1, 42, 42.1, 43, 43.1, 44, 44.1, 45, 45.1, 46, 46.1, 47, 47.1, 48, 48.1, 49, 49.1, 50, 50.1, 51, 51.1, 52, 52.1, 53, 53.1, 54, 54.1, 55 and 56.